100 percent Bio-Based Production
Production from renewable sugars completely eliminates reliance on Propylene and petroleum.
Isopropanol (IPA) is one of the most widely used industrial chemicals globally, serving as a critical component in Solvents/Disinfectants, pharmaceutical manufacturing, and electronics cleaning. The current supply chain is highly vulnerable: Traditionally petrochemical-derived from Propylene. This reliance on volatile fossil fuel feedstocks results in price instability and a large carbon footprint.
CD Biosynsis offers a two-stage biological solution for sustainable IPA production: Metabolic Engineering: Introduce a synthetic pathway in E. coli or yeast to produce Isopropanol from Acetone (a Clostridial by-product) using Secondary Alcohol Dehydrogenase. This enzymatic reduction offers high specificity. Crucially, we Engineer the host to channel carbon flux to Acetone production from renewable sugars, integrating the two steps into an efficient fermentation process to replace petroleum-based synthesis entirely.
Get a QuoteThe traditional petrochemical synthesis of Isopropanol IPA suffers from these issues:
A biological process provides a direct, low-temperature, and sustainable alternative to petrochemical synthesis.
CD Biosynsis engineers an integrated Acetone-to-IPA biocatalytic route:
Acetone Reduction to IPA Pathway
We introduce a synthetic pathway using Secondary Alcohol Dehydrogenase SADH to convert Acetone to IPA in E. coli or yeast.
Enhanced Acetone Precursor Supply
We engineer the host to channel carbon flux from sugar e.g. glucose to Acetone production, creating a direct Acetone supply chain for SADH.
Cofactor Regeneration Optimization
SADH requires a cofactor NADPH. We metabolically optimize NADPH regeneration pathways e.g. pentose phosphate pathway to ensure sufficient reducing power for IPA synthesis.
Solvent Tolerance and Export
We engineer the host for increased tolerance to IPA and Acetone and introduce efflux pumps to continuously secrete the product, boosting titer.
This biological pathway is renewable, highly selective, and operates under ambient conditions.
Our Isopropanol IPA engineering service offers these core benefits:
100 percent Bio-Based Production
Production from renewable sugars completely eliminates reliance on Propylene and petroleum.
Mild Operating Conditions Icon
Enzymatic conversion occurs at low temperature and pressure, drastically reducing energy consumption compared to petrochemical routes.
High Specificity Conversion
SADH catalysis is highly selective Acetone-to-IPA, minimizing byproducts and simplifying purification.
Reduced Waste Streams
The non-corrosive, aqueous fermentation process eliminates the harsh acidic waste associated with petrochemical synthesis.
Cost-Effective Titer Achievement
Metabolic flux optimization and tolerance improvement lead to competitive IPA titers for economical downstream processing.
We provide a sustainable and cost-competitive path for IPA production from renewable sources.
Our Isopropanol IPA engineering service follows a rigorous, multi-stage research workflow:
Technical communication is maintained throughout the process, focusing on timely feedback regarding yield and product tolerance attributes.
Explore the potential for a sustainable, cost-effective Isopropanol IPA supply. CD Biosynsis provides customized strain and process engineering solutions:
Why use Acetone as an intermediate for IPA synthesis?
The conversion of Acetone to IPA via Secondary Alcohol Dehydrogenase SADH is a simple, single-step, highly specific enzymatic reaction. Acetone is a natural byproduct of the ABE fermentation pathway found in Clostridium strains. By adapting this pathway in a faster-growing host like E. coli, we create an efficient two-stage biosynthesis route from sugar to IPA.
What is the role of SADH Secondary Alcohol Dehydrogenase?
SADH is the key enzyme that catalyzes the reduction of a ketone Acetone into a secondary alcohol IPA. This reaction requires a cofactor NADPH. We selectively engineer and optimize SADH variants to ensure maximal reaction rate and minimal side products, making the final product highly pure and selective.
How do you counteract IPA toxicity to achieve high titer?
IPA is a toxic solvent. To reach commercially viable titers, we use two strategies: first, we improve the strain tolerance through membrane engineering and efflux pumps. Second, we implement in situ product removal ISPR techniques e.g. pervaporation or gas stripping to continuously remove IPA from the broth as it is formed, keeping the cellular concentration low.
What is the estimated project timeline?
A comprehensive project involving Acetone precursor engineering, SADH optimization, and tolerance improvement typically requires 30-40 weeks for final strain delivery and validated IPA production protocol.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.